Erythromycin
NDC Package 0074-6301-53

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Erythromycin is a medication used to treat certain eye infections (such as conjunctivitis). Marketed by Abbott Laboratories, this product is identified by NDC 0074-6301 and is authorized under FDA application ANDA062746.

Identification & Billing

NDC Package Code
0074-6301-53
Package Description
500 CAPSULE, DELAYED RELEASE in 1 BOTTLE
Product Code
0074-6301
11-Digit Billing Format
00074630153

Clinical Specifications

Proprietary Name
Erythromycin
Dosage Form
-
Usage Information
This medication is used to treat certain eye infections (such as conjunctivitis). It is also used to prevent certain eye infections in newborns. It belongs to a class of drugs known as macrolide antibiotics. Erythromycin works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Regulatory & Marketing

Labeler Name
Abbott Laboratories
FDA Application #
ANDA062746
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-22-1986
End Marketing Date
09-01-2012
Listing Expiration
09-01-2012
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0074-6301). Click a package code to view its specific billing and regulatory data.

0074-6301-13
100 CAPSULE, DELAYED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-6301-53 identifies a specific commercial package of 500 capsule, delayed release in 1 bottle of Erythromycin, labeled by Abbott Laboratories. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Abbott Laboratories on December 22, 1986. The current certification is valid through September 01, 2012.

What are the primary indications for this medication?

This medication is used to treat certain eye infections (such as conjunctivitis). It is also used to prevent certain eye infections in newborns. It belongs to a class of drugs known as macrolide antibiotics. Erythromycin works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

How is this Abbott Laboratories product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074630153. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-6301-53
11-Digit CMS (5-4-2)
00074-6301-53

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.